logo
logo

Akero Therapeutics Announces Two Financing Transactions With Pfizer Inc. And Hercules Capital, Inc. Providing Access To Up To $125 Million

Jun 16, 2022•over 3 years ago
San FranciscoTherapeuticsBiotechnologyHealth Care

Description

Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced two financing transactions. The first is a $25 million equity investment by Pfizer Inc. (NYSE: PFE) at $9.90 per share

Company Information

Company

Akero Therapeutics

Location

San Francisco, California, United States

About

Akero Therapeutics is a clinical-stage cardio-metabolic company developing transformational treatments for non-alcoholic steatohepatitis (NASH), a disease without any approved therapies. Akero's lead product candidate, efruxifermin (EFX), an engineered Fc-FGF21 fusion protein, is currently being evaluated in a Phase 2b clinical trial as a potential treatment for NASH. Akero is headquartered in South San Francisco.

Related People